Newsroom
Sorted by: Latest
-
Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026
TOKYO--(BUSINESS WIRE)--Kioxia will showcase the innovations driving the performance, scalability, and efficiency required for next-generation AI infrastructure at FMS 2026....
-
Samenvatting: Thales versterkt de bescherming van het Roemeense luchtruim met twaalf Ground Master 200 MM/A radars
MEUDON, Frankrijk--(BUSINESS WIRE)--In een context van toenemende samenwerking tussen Europese landen om de gezamenlijke beveiliging te verbeteren, heeft het Roemeense General Directorate for Armaments onlangs een belangrijke overeenkomst ondertekend met het Franse DGA (Direction Générale de l’Armement) om twaalf Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars aan te kopen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshu...
-
Computershare Trustees (Jersey) Limited UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. Fo...
-
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care
SAN DIEGO--(BUSINESS WIRE)--LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,...
-
Streamlabs Launches Network Boost: Flawless IRL Streaming, Zero Expensive Hardware
LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--Logitech G Streamlabs today announced Network Boost, a new mobile feature for Streamlabs Ultra that helps creators improve stream reliability by combining multiple internet connections using the devices they already own. As IRL streaming skyrockets, with Twitch viewers consuming over 391 million hours of IRL content last year alone, unstable cellular connections on crowded convention floors or city streets remain a massive barrier. Hist...
-
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network
SENDAI, Japan--(BUSINESS WIRE)--Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existi...
-
Evexta Bio annonce une collaboration clinique et un contrat d'approvisionnement avec Roche afin d'évaluer le rupitasertib en association avec un dégradateur sélectif des récepteurs des œstrogènes dans le cancer du sein avancé ou métastatique
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., une société d'oncologie de précision fondée par Truffle Capital (fondateur d'Abivax et de Carvolix) et consacrée à la découverte et au développement de thérapies ciblées, annonce aujourd'hui la signature d’un contrat de collaboration clinique et d’approvisionnement afin d’effectuer une étude de phase 1b associant son principal candidat médicament, le rupitasertib, avec un produit en développement de Roche, le giredestrant, un dégradateur sélectif des réc...
-
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-m...
-
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board
CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologis...
-
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 25
TOKYO--(BUSINESS WIRE)--The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@G...